Loading…
Loading…
BMRN does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for BMRN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for BMRN and 80,000+ other tickers.
See exactly how BMRN's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BMRN and 80,000+ other tickers.
BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for…
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assenagon Asset Management S.A. trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,339,560 shares of the biotechnology company's stock after selling 422,526 shares during
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk. Analyst Recommendations This is a summary of recent
New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting (ASBMR) in Boston, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia.